Efficacy and safety of doripenem for sepsis with neutropenia in Japanese patients with hematologic diseases.

Abstract

Doripenem (DRPM) is one of the carbapenems which has a broad-spectrum and strong activity against Pseudomonas aeruginosa. This observational study was conducted between April 2006 and March 2007 in Japan to evaluate the efficacy and safety of DRPM 0.5 g three times a day for sepsis with neutropenia in patients with hematologic diseases. One hundred-nineteen patients were enrolled from 34 medical institutes, comprising 117 patients for safety evaluation and 104 for efficacy evaluation. Monotherapy of DRPM 0.5 g three times a day (DRPM monotherapy) was evaluated in 73 patients. The response rates of DRPM monotherapy at 72 hours and at Day 7 were 31.5% (23/73) and 67.1% (49/73), respectively. The incidence of adverse reactions including abnormal changes in laboratory values was 23.1%, and hepatic toxicity was most common. All of these adverse events were judged by the investigators as non-serious and tolerable. These results suggest that DRPM is useful for sepsis with neutropenia, though further study may be warranted.

• Authors: Nobu Akiyama, Akihisa Kanamaru, Kazuo Tamura, Mitsune Tanimoto, Kazuma Ohyashiki, Yasunori Nakagawa, Akio Urabe, Toru Masaoka
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 65 Issue 4 Pg. 251-62 (Aug 2012) ISSN: 0368-2781 [Print] Japan
• PMID: 23259255 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Carbapenems
• Doripenem

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anti-Bacterial Agents (therapeutic use)
• Carbapenems (adverse effects, therapeutic use)
• Doripenem
• Female
• Humans
• Liver (drug effects)
• Male
• Middle Aged
• Neutropenia (drug therapy)
• Prospective Studies
• Sepsis (drug therapy)